Relmada Therapeutics (RLMD) Cash & Equivalents (2012 - 2026)

Relmada Therapeutics (RLMD) has 15 years of Cash & Equivalents data on file, last reported at $9.8 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 750.34% year-over-year to $9.8 million in Q1 2026; TTM through Mar 2026 was $9.8 million, a 750.34% increase from a year earlier, with the FY2025 full-year figure at $3.5 million, down 9.35% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $9.8 million, up from $3.5 million in the prior quarter.
• Over the last five years, Cash & Equivalents for RLMD reached as high as $44.9 million in Q1 2022 and fell as low as $1.1 million in Q1 2025.
• Historically, Cash & Equivalents has averaged $12.4 million across 5 years, with a median of $4.1 million in 2023.
• Across the five-year window, Cash & Equivalents surged 1081.23% in 2022 and plunged 95.38% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $5.4 million in 2022, then slipped by 24.17% to $4.1 million in 2023, then decreased by 5.73% to $3.9 million in 2024, then dropped by 9.35% to $3.5 million in 2025, then surged by 179.6% to $9.8 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $9.8 million in Q1 2026, $3.5 million in Q4 2025, and $1.4 million in Q3 2025.